Post hoc pooled analysis of three phase 3 trials (3,660 patients): inclisiran lowered LDL cholesterol versus placebo by about 45-55% at day 510 across all eGFR categories down to 15 ml/min/1.73 m2, with no new safety findings.
Secondary analysisn = 3,660 patients
Landmesser et al. Inclisiran in Patients with CKD: Post Hoc Pooled Analysis of Three Phase 3 Trials